Adam M. Swartz

609 citations
18 papers · 364 indexed · h-index 10
Topics
Immunotherapy and Immune Responses (14 papers)CAR-T cell therapy research (8 papers)RNA Interference and Gene Delivery (6 papers)
Partner nations
United States

In The Last Decade

Adam M. Swartz

18 papers receiving 359 citations

Peers

Adam M. Swartz
Comparison fields: 5 of 45
  • Immunology 206
  • Oncology 196
  • Molecular Biology 126
  • Genetics 120
  • Biomedical Engineering 45
Replace Maki Ikeura with:
Maki Ikeura United States
Jaime Richardson United States
Catherine Flores United States
D. D. Bigner United States
Aditya Mohan United States
Sabrina Genßler Germany
Alba Matas‐Céspedes Spain
Monica Epstein United States
Michael Kilian Germany
Chujun Zhao China
Adam M. Swartz relative to Maki Ikeura United States Maki Ikeura's profile →
Citations per field
00.5×1.5×1.9×
Maki Ikeura · 1×
Citations per year

Countries citing papers authored by Adam M. Swartz

Since Specialization
Citations

This map shows the geographic impact of Adam M. Swartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam M. Swartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam M. Swartz more than expected).

Fields of papers citing papers by Adam M. Swartz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam M. Swartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam M. Swartz. The network helps show where Adam M. Swartz may publish in the future.

Co-authorship network of co-authors of Adam M. Swartz

This figure shows the co-authorship network connecting the top 25 collaborators of Adam M. Swartz. A scholar is included among the top collaborators of Adam M. Swartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam M. Swartz. Adam M. Swartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
#WorkIndexed citations
1 37
2 16
3 3
4 6
5 11
6 2
7 1
8 48
9 10
10 5
11 12
12 55
13 7
14 3
15 16
16 48
17 78
18 6

About Adam M. Swartz

Adam M. Swartz is a scholar working on Immunology, Oncology and Molecular Biology, having authored 18 papers that have together received 364 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (14 papers), CAR-T cell therapy research (8 papers) and RNA Interference and Gene Delivery (6 papers). The work is most often cited by research in Genetics (120 citations), Immunology (206 citations) and Oncology (196 citations). Adam M. Swartz has collaborated with scholars based in United States. Frequent co-authors include John H. Sampson, Qi-Jing Li, Kristen A. Batich, Peter E. Fecci, Smita K. Nair, Luis Sánchez-Pérez, James E. Herndon, Carter M. Suryadevara, Elizabeth A. Reap and Michael D. Gunn. Their work appears in journals such as Journal of Clinical Investigation, Nature Genetics and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026